[
  {
    "ts": null,
    "headline": "The Score: Meta Platforms, Moderna, Edison International and More Stocks That Defined the Week",
    "summary": "The Score: Meta Platforms, Moderna, Edison International and More Stocks That Defined the Week",
    "url": "https://finnhub.io/api/news?id=867641c8445aea0ba095d2a736e7bd0e083ae8b56d1a4e978cf85fe61643a988",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736530260,
      "headline": "The Score: Meta Platforms, Moderna, Edison International and More Stocks That Defined the Week",
      "id": 132535229,
      "image": "",
      "related": "MRNA",
      "source": "DowJones",
      "summary": "The Score: Meta Platforms, Moderna, Edison International and More Stocks That Defined the Week",
      "url": "https://finnhub.io/api/news?id=867641c8445aea0ba095d2a736e7bd0e083ae8b56d1a4e978cf85fe61643a988"
    }
  },
  {
    "ts": null,
    "headline": "AI, vaccine distrust, & the future of healthcare: Novartis CEO",
    "summary": "Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart a stock price that has lagged in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.",
    "url": "https://finnhub.io/api/news?id=be29e0e1d1de1f0cf67bbfce15ae9d05e3410ad5a5cd4340317e7ad82a5f045e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736515851,
      "headline": "AI, vaccine distrust, & the future of healthcare: Novartis CEO",
      "id": 132363849,
      "image": "https://s.yimg.com/ny/api/res/1.2/lYz92SON.CgZn.4L3FSanQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/c2a28a10-ced6-11ef-8ffe-41aa770da203",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart a stock price that has lagged in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.",
      "url": "https://finnhub.io/api/news?id=be29e0e1d1de1f0cf67bbfce15ae9d05e3410ad5a5cd4340317e7ad82a5f045e"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)",
    "summary": "Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads significantly. Read my MRNA analysis.",
    "url": "https://finnhub.io/api/news?id=7a179398d452e048fd45e6eb667c2a03c915ed48007bcc24820566dbd4e2bc30",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736499600,
      "headline": "Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)",
      "id": 132363177,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159351609/image_2159351609.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads significantly. Read my MRNA analysis.",
      "url": "https://finnhub.io/api/news?id=7a179398d452e048fd45e6eb667c2a03c915ed48007bcc24820566dbd4e2bc30"
    }
  }
]